Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelica Cuapio

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Scientific Reports|June 23, 2022
Long-COVID in children and adolescents: a systematic review and meta-analysesSandra Lopez-Leon, Talia Wegman-Ostrosky, Norma Cipatli Ayuzo Del Valle, et al.
Journal of Autoimmunity|February 3, 2015
The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammationAnne Rissiek, Isabell Baumann, Angelica Cuapio, et al.
Frontiers in Immunology|October 16, 2018
Cell-Mediated Immune Responses and Immunopathogenesis of Human Tick-Borne Encephalitis Virus-InfectionKim Blom, Angelica Cuapio, J Tyler Sandberg, et al.
Frontiers in Immunology|May 31, 2017
The Transcription Factor ZNF683/HOBIT Regulates Human NK-Cell DevelopmentMirte Post, Angelica Cuapio, Markus Osl, et al.
Haematologica|January 20, 2022
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trialLisa Blixt, David Wullimann, Soo Aleman, et al.
Molecular Medicine (Cambridge, Mass.)|May 13, 2022
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccineCaroline Boulouis, Tobias Kammann, Angelica Cuapio, et al.
Ebiomedicine|July 15, 2023
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Ebiomedicine|May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunityPuran Chen, Peter Bergman, Ola Blennow, et al.
Ebiomedicine|October 12, 2024
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Immunity|February 15, 2015
Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attackChamutal Gur, Yara Ibrahim, Batya Isaacson, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Scientific Reports|June 23, 2022
Long-COVID in children and adolescents: a systematic review and meta-analysesSandra Lopez-Leon, Talia Wegman-Ostrosky, Norma Cipatli Ayuzo Del Valle, et al.
Journal of Autoimmunity|February 3, 2015
The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammationAnne Rissiek, Isabell Baumann, Angelica Cuapio, et al.
Frontiers in Immunology|October 16, 2018
Cell-Mediated Immune Responses and Immunopathogenesis of Human Tick-Borne Encephalitis Virus-InfectionKim Blom, Angelica Cuapio, J Tyler Sandberg, et al.
Frontiers in Immunology|May 31, 2017
The Transcription Factor ZNF683/HOBIT Regulates Human NK-Cell DevelopmentMirte Post, Angelica Cuapio, Markus Osl, et al.
Haematologica|January 20, 2022
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trialLisa Blixt, David Wullimann, Soo Aleman, et al.
Molecular Medicine (Cambridge, Mass.)|May 13, 2022
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccineCaroline Boulouis, Tobias Kammann, Angelica Cuapio, et al.
Ebiomedicine|July 15, 2023
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Ebiomedicine|May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunityPuran Chen, Peter Bergman, Ola Blennow, et al.
Ebiomedicine|October 12, 2024
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Immunity|February 15, 2015
Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attackChamutal Gur, Yara Ibrahim, Batya Isaacson, et al.
Pageof 3